Clinical Trials Related to Primary Peritoneal Cancer

Related studies linked through entity extraction aliases.

Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer

Status: COMPLETED
Phase: PHASE1/PHASE2

Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer

Status: COMPLETED
Phase: PHASE2

Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer

Status: COMPLETED
Phase: PHASE1

Autologous OC-L Vaccine and Ovarian Cancer

Status: TERMINATED
Phase: PHASE1

p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Status: UNKNOWN
Phase: PHASE2

Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission

Status: COMPLETED
Phase: PHASE1

Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Status: TERMINATED
Phase: PHASE2

Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Status: COMPLETED
Phase: PHASE1

GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer

Status: TERMINATED
Phase: PHASE1/PHASE2

Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations

Status: COMPLETED
Phase: PHASE1/PHASE2

PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer

Status: COMPLETED
Phase: PHASE2

"Re-Stimulated" TILs and IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1

Tai-chi / Qi-gong in Patients With Patients With Gynecological Malignancies

Status: WITHDRAWN
Phase: PHASE1/PHASE2

Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer

Status: TERMINATED
Phase: NA

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Status: COMPLETED
Phase: PHASE2

A Study LY2228820 for Recurrent Ovarian Cancer

Status: COMPLETED
Phase: PHASE1/PHASE2

CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer

Status: COMPLETED
Phase: PHASE2

A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Status: UNKNOWN
Phase: PHASE2

Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Status: COMPLETED
Phase: PHASE1

A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Status: TERMINATED
Phase: PHASE1/PHASE2